Novosom AG, of Halle, Germany, and Nucleonics Inc., of Horsham, Pa., entered an agreement to develop Nucleonics' expressed RNA interference-based (eiRNA) therapeutics with Novosom's delivery technology.(Other News To Note)(Brief Article)

* Novosom AG, of Halle, Germany, and Nucleonics Inc., of Horsham, Pa., entered an agreement to develop Nucleonics' expressed RNA interference-based (eiRNA) therapeutics with Novosom's delivery technology. Specifically, the companies will evaluate Novosom's Smarticles formulation technology for the delivery of Nucleonics' lead eiRNA candidates for hepatitis B and C. In addition, privately held Nucleonics has taken an option to exclusively license and commercialize the technology for its eiRNA therapeutics in those indications. Financial terms were not disclosed.